Back to Landing Page »

The First and Only EZH2 Inhibitor Indicated for Patients with Relapsed or Refractory Follicular Lymphoma

Marin Xavier, MD
John Pagel, MD, PhD


Published

February 1, 2021

Created by

Scripps CME Connection